Acquired Company

Ono Pharmaceutical completed its $2.4 billion acquisition of Deciphera Pharmaceuticals on 6/10/2024, acquiring all outstanding shares for $25.60 per share in cash.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts. Show more

200 SMITH STREET, WALTHAM, MA, UNITED STATES, 02451, Massachusetts, 02451-0099, USA

https://www.deciphera.com

DRUG MANUFACTURERS - SPECIALTY & GENERIC

HEALTHCARE

Start AI Chat

Market Cap

2.213B

52 Wk Range

$0.00 - $0.00

Previous Close

$25.59

Open

$25.59

Volume

N/A

Day Range

$25.59 - $25.59

Enterprise Value

0.00

Cash

91.23M

Avg Qtr Burn

-54.59M

Insider Ownership

28.48%

Institutional Own.

72.03%

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details GIST (Gastrointestinal stromal tumors) (fourth-line)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Tenosynovial Giant Cell Tumors, Cancer	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Qinlock (Ripretinib) Details Gastrointestinal stromal tumors	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Cancer, Tenosynovial Giant Cell Tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK) + trametinib, sotorasib & binimetin Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+Qinlock Details Solid tumor/s, Gastrointestinal stromal tumors	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DCC-3116 (Inhibitor of ULK)+encorafenib & cetuximab Details Solid tumor/s, Colorectal cancer , Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rebastinib (TIE2 inhibitor) + Paclitaxel Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.